Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00280839 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
A Phase 3 study of Smoking Cessation, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT00280839: Completed Phase 3 study of Smoking Cessation, sponsored by Lindner Center of HOPE.
NCT00280839 is a Phase 3 study of Smoking Cessation that has completed, run by Lindner Center of HOPE. The registered enrollment target is 87 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00280839, a Phase 3 study of Smoking Cessation, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if topiramate is safe and effective in the treatment of smoking cessation
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Topiramate
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Phase | Phase 3 |
What the finished NCT00280839 record still lists
NCT00280839 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00280839 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00280839 about?
NCT00280839 is a clinical study titled "Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation". The purpose of this research study is to determine if topiramate is safe and effective in the treatment of smoking cessation
What is the current status of trial NCT00280839?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants.
What conditions does trial NCT00280839 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00280839?
The interventions under investigation include: Placebo (DRUG), Topiramate (DRUG).
Who is sponsoring clinical trial NCT00280839?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00280839 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00280839's enrollment target sits among peer trials
87 123rd of 188 higher than 66 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Nicotine Mouth Film for Craving Relief.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer